INDV — Indivior Pharmaceuticals, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2023-06-12.
Performance
Technicals
Others in Healthcare
Measured signals that fired on INDV
| date | signal | measured base rate |
|---|---|---|
| 2026-08-03 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-06-04 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-06-02 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-04-30 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-04-01 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-03-13 | Volume shock without a price move price | -1.33% over 21 days · t = -4.53 · n = 16,432 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-05 | Anderson Woodrow D Chief Accounting Officer | Open-market purchase | 1.5K | 36.28 | 54.4K |
| 2026-07-10 | Heidbreder Christian Chief Scientific Officer | Open-market sale 10b5-1 plan | 18.6K | 41.14 | 764.6K |
| 2026-06-22 | Ciaffoni Joseph Chief Executive Officer | Shares withheld for tax | 612.5K | 38.32 | 23.5M |
| 2026-06-22 | Ciaffoni Joseph Chief Executive Officer | Option exercise | 1.3M | — | — |
| 2026-06-11 | Heidbreder Christian Chief Scientific Officer | Open-market sale 10b5-1 plan | 18.6K | 38.06 | 707.4K |
| 2026-06-08 | Preblick Ryan Chief Financial Officer | Open-market sale 10b5-1 plan | 36.0K | 37.70 | 1.4M |
| 2026-05-13 | Stejbach Mark Director | Grant or award | 6.5K | 0.00 | 0 |
| 2026-05-13 | Kingsley Stuart A Director | Grant or award | 6.5K | 0.00 | 0 |
| 2026-05-13 | NINIVAGGI DANIEL A Director | Grant or award | 6.5K | 0.00 | 0 |
| 2026-05-13 | Humphreys Keith Director | Grant or award | 6.5K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BlackRock, Inc. | 565.2M | 18.5M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 240.5M | 7.9M |
| OAKTREE CAPITAL MANAGEMENT LP | 212.9M | 7.0M |
| VANGUARD CAPITAL MANAGEMENT LLC | 170.3M | 5.6M |
| STATE STREET CORP | 149.5M | 4.9M |
| Two Seas Capital LP | 144.7M | 4.7M |
| MILLENNIUM MANAGEMENT LLC | 140.1M | 4.6M |
| FULLER & THALER ASSET MANAGEMENT, INC. | 138.1M | 4.5M |
| Madison Avenue Partners, LP | 131.5M | 4.3M |
| CITADEL ADVISORS LLC | 108.9M | 3.6M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Ask the AI about INDV
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →